April 18th 2024
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Single-Agent Paclitaxel in Advanced Non–Small-Cell Lung Cancer
September 1st 1999Despite the availability of combination chemotherapy, response rates are poor in patients with non–small-cell lung cancer. Recently, phase II trials have been undertaken with single-agent paclitaxel (Taxol). Good results have
Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
September 1st 1999Despite a response rate of only 9%, single-agent carboplatin (Paraplatin) produced the best 1-year survival rate with the lowest toxicity in a five-arm Eastern Cooperative Oncology Group study of cisplatin (Platinol)
Quality-of-Life Improvement in Patients Receiving Paclitaxel/Platinum Regimens
September 1st 1999The combination regimen of paclitaxel (Taxol) and cisplatin (Platinol) for non–small-cell lung cancer has shown improved response rates in some phase II trials, and because of its safety profile, it could offer patients with this
New Insights Into the Cost-Effectiveness of Lung Cancer Treatment
September 1st 1999Despite growing evidence that patients with advanced non–small-cell lung cancer have improved survival and better symptom control with modern systemic therapy, there is still resistance to the use of chemotherapy because
The Emerging Role of Paclitaxel Plus Carboplatin in Non–Small-Cell Lung Cancer
September 1st 1999The activity and toxicity profiles of carboplatin (Paraplatin) and paclitaxel (Taxol) used as single agents in non–small-cell lung cancer made them logical agents for study in combination therapy. Once preliminary trials
To Treat or Not to Treat Non–Small-Cell Lung Cancer Patients? Current Perspectives
September 1st 1999In the 1980s, the introduction of cisplatin (Platinol)-based chemotherapy prolonged survival and improved quality of life in patients with stage III and IV non–small-cell lung cancer. More recently, the use of five new
Study Confirms Value of Paclitaxel Plus Paraplatin in NSCLC
August 1st 1999According to the results of a landmark phase III, multicenter, Southwest Oncology Group clinical trial (SWOG 9509), the use of paclitaxel (Taxol) plus carboplatin (Paraplatin) can be considered a standard regimen for non–small-cell lung cancer
Spiral CT Finds Early-Stage Lung Cancer
August 1st 1999NEW YORK-Screening of smokers with helical (spiral) low-dose computed tomography (CT) is more likely than chest x-rays to find malignant tumors, and the tumors are “substantially smaller than those detected on chest radiography,” said Claudia I. Henschke, MD, of New York Presbyterian Hospital-Weill Cornell Medical Center.
Genes Linked to Smoking Affinity, Smoking-Induced Lung Cancer
July 1st 1999PHILADELPHIA-Research shows that genetic makeup may offer a clue to an individual’s affinity for smoking and propensity to develop lung cancer, investigators said at the annual meeting of the American Association for Cancer Research (AACR).
UFT Plus Cisplatin With Concurrent Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer
A phase II study of combined-modality treatment consisting of uracil and tegafur (in a molar ratio of 4:1 [UFT]) plus cisplatin (Platinol) and concurrent radiotherapy was conducted to evaluate the activity of this regimen in
Variations Mark Overall Fall in Cancer Incidence, Mortality
June 1st 1999WASHINGTON-Overall incidence and mortality rates for cancer continue to decline in the United States. However, a new report finds considerable disparities among racial and ethnic groups, and it warns that a resurgence of smoking among teen-agers forewarns of a likely reversal of the downward trend, especially for lung cancer.
Age Should Not Determine Treatment of SCLC Patients
May 1st 1999A study published in a recent issue of the International Journal of Radiation Oncology, Biology, and Physics found that elderly patients with limited small-cell lung cancer (SCLC) can tolerate radiation and should not be denied potentially curative
Single Chest X-Ray Leads to Improved Lung Cancer Prognosis
May 1st 1999Finnish investigators recently reported that the survival rates of patients whose lung cancer was found during screening with a single chest radiograph were significantly higher than survival rates in patients whose cancer was detected through “the
Commentary (Keller): Surgical Staging of Lung Cancer
May 1st 1999As Matin and Goldberg note, the accurate staging of non-small-cell lung cancer (NSCLC) is necessary to provide patients with correct information regarding prognosis and appropriate treatment recommendations. Therefore, physicians who treat
Commentary (Ginsberg): Surgical Staging of Lung Cancer
May 1st 1999Drs. Matin and Goldberg describe and comment on the invasive techniques currently used for the clinical staging of lung cancer. Although they term this “surgical” staging, in reality, it is part of clinical staging (cTNM) and should be distinguished
Medicare Covers Three New PET Uses in Cancer Diagnosis and Treatment
April 1st 1999WASHINGTON-Medicare will cover three additional uses of positron emission tomography (PET) for the diagnosis and treatment of cancer. In addition to the previously covered uses for the diagnostic evaluation of solitary pulmonary nodules and for staging non-small-cell lung cancer, PET will now be covered for the detection and localization of recurrent colorectal cancer with rising CEA levels; the staging and characterization of both Hodgkin’s and non-Hodgkin’s lymphoma in place of a gallium scan or lymphangiogram; and the identification of metastases in melanoma recurrence in place of gallium scans.
PDT ‘Seems Better’ Than Laser for Bronchial Obstruction
April 1st 1999SAN ANTONIO-Photodynamic therapy (PDT) with porfimer sodium (Photofrin) in patients with endobronchial obstruction due to locally advanced lung cancer appears to be at least as good as an Nd-YAG laser for palliation and “probably better,” Harvey I. Pass, MD, said at a satellite symposium of the Society for Thoracic Surgeons meeting.
Patients Need to Understand Cancer Testing Limitations
March 1st 1999NEW YORK-A man wanted to know why his chest x-ray was normal 4 months before he was diagnosed with stage IV lung cancer. A woman wanted to know how her mother could have negative tumor markers and seven brain metastases at the same time.
Navelbine Increased Elderly Lung Cancer Patients’ Survival
March 1st 1999Elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine tartrate (Navelbine) injection enjoy improved survival over those receiving best supportive care, according to a study published in the February issue of the Journal of the National Cancer Institute.